CGM can provide valuable insight into islet graft performance after TPIAT, according to a study published in Diabetes Technology & Therapeutics. Conducted at Verona University Hospital, the study followed 10 adults with pancreatic neoplasms who underwent TPIAT between 2023 and 2025.

Participants were monitored using CGM at 3, 6, and 12 months after surgery. Islet function was assessed using the Igls classification and BETA-2 score, resulting in 25 total evaluations categorized as optimal, good, marginal, or failed. Patients with optimal graft function achieved excellent glycemic stability, with TIR of 97.0%, TITR of 86.5%, and time above range (TAR) of 1.5%. These patients also showed lower glycemic variability, with a coefficient of variation (CV) of 20.5% and a glycemia risk index (GRI) of 44.0.

All CGM-derived parameters correlated significantly with both Igls classification and BETA-2 score (P < 0.015), indicating that CGM metrics reliably reflect β-cell function after TPIAT. The study suggests that integrating CGM-based monitoring into post-transplant care could enhance long-term metabolic management and provide clinicians with a sensitive, noninvasive tool for endocrine follow-up.